Pfizer Positions For First-In-Class Nasal Corticosteroid Switch
This article was originally published in The Tan Sheet
Rhinocort Aqua could be a first-in-class U.S. switch for the nasal corticosteroids, often cited as a potential class for switches. Pfizer gains right of first refusal for the product’s OTC rights from AstraZeneca.
You may also be interested in...
Nexium OTC Switch Would Face Crowded Field, Potential Questions
Pfizer will pay AstraZeneca $250 million upfront for global rights to market a potential OTC 20-mg Nexium. Pharma marketing expert Joe McGovern expects Nexium “to start OTC with a big bang,” but Center for Consumer Self Care Executive Director Bill Soller points to potential safety questions about a switch.
Novartis makes OTC exec change following recall and plant shutdown; Prestige Brands adopts plan to deter Genomma takeover bid; Pfizer scoops up Emergen-C maker Alacer; CSPI threatens Amway with Nutrilite suit; more news In Brief.
Pfizer Plans To Give Diversified Businesses Time To Grow
Pfizer plans to give its consumer products businesses "the opportunity to grow" as it integrates Wyeth into its operations, according to CEO Jeffrey Kindler